LENSAR (LNSR) Competitors

LENSAR (NASDAQ:LNSR) and Bioventus (NYSE:BVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Do institutionals and insiders hold more shares of LNSR or BVS?

40.2% of LENSAR shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 38.5% of LENSAR shares are held by insiders. Comparatively, 33.0% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has more risk and volatility, LNSR or BVS?

LENSAR has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

Does the media prefer LNSR or BVS?

In the previous week, LENSAR's average media sentiment score of 1.76 beat Bioventus' score of 0.00 indicating that LENSAR is being referred to more favorably in the media.

Company	Overall Sentiment
LENSAR	Very Positive
Bioventus	Neutral

Do analysts prefer LNSR or BVS?

LENSAR presently has a consensus price target of $15.00, suggesting a potential upside of 16.28%. Bioventus has a consensus price target of $13.75, suggesting a potential upside of 79.97%. Given Bioventus' stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Which has higher valuation & earnings, LNSR or BVS?

LENSAR has higher earnings, but lower revenue than Bioventus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$53.49M	2.88	-$31.40M	-$4.21	-3.06
Bioventus	$564.14M	1.12	-$156.23M	N/A	N/A

Is LNSR or BVS more profitable?

Bioventus has a net margin of -7.11% compared to LENSAR's net margin of -84.49%. Bioventus' return on equity of 15.61% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	-84.49%	-737.30%	-72.60%
Bioventus	-7.11%	15.61%	4.01%

Summary

Bioventus beats LENSAR on 9 of the 14 factors compared between the two stocks.